The sequencing of the human genome in 2003 was a landmark event in the human quest for understanding diseases and discovering new drugs to treat them. Since then, biomedical research has evolved to incorporate the deluge of new DNA sequence information and to address the computational challenges of transforming that knowledge into insight on disease-associated protein functions. But the capabilities to reach the required breakthroughs have proven well beyond those traditionally available to a single company. As a result, organisations like the European Bioinformatics Institute unit at the European Molecular Biology Laboratory, the Wellcome Sanger Institute, GlaxoSmithKlein, Biogen, Takeda, Celgene and Sanofi are creating partnerships and platforms that allow them to pool data, technologies and research capabilities to accelerate drug discovery.
At this high-level webinar, Dr Ian Dunham, director of Open Targets, a large-scale consortium and platform created in 2015 to collaboratively establish the links between genetic targets and disease development, will present the Open Targets initiative. Dr Dunham will look at the challenges of biomedical research today and how ideas about a “data commons” and pre-competitive collaboration across private and public organizations can effectively accelerate drug discovery. He will explore the policy challenges needed to deepen Europe’s footprint in this key area and describe the contribution that “open targets” have already made, including the identification of 600 cancer-enabling genes and the creation of the first Human Cell Atlas for the lungs, which is expected to radically improve asthma relief.
Dr Dunham will be joined at this registration-only webinar by leading experts from the Open Science Monitor for a discussion of the challenges – and solutions – to accelerate scientific data sharing and collaboration in biomedical research.
Special Guest: - Dr Ian Dunham, director, Open Targets
High-Level Presenters: - David Osimo, director of research, the Lisbon Council
- Laia Pujol Priego, researcher, ESADE Business School; co-author, Open Targets Case Study, Open Science Monitor
Only registered participants will have access to the webinar. About the Open Science Monitor The Open Science Monitor is a project initiated by the European Commission in 2015 to gather insight on the on-going development of open-science practices and to foster open-science policy as a result. Co-managed by the Lisbon Council, ESADE Business and Law School and the Centre for Science and Technology Studies (CWTS) at Leiden University, the Open Science Monitor provides data and insight to understand the development of open science in Europe. The Open Science Monitor also supports European Commission initiatives such as the Open Science Policy Platform and the Open Science Cloud. For more information, visit the Open Science Monitor. |